Abcalis® anti-SARS-CoV-2 antibodies are high quality recombinant monoclonal primary antibodies
Abcalis’ product portfolio now also features anti-SARS-CoV-2 recombinant (sequence defined) monoclonal antibodies. We believe that recombinant primary antibodies can deliver a significant improvement over the current standard testing procedure of utilizing RT-PCR testing. Given that RT-PCR tests are complex, cost-intensive and time-consuming, the tests are not truly suitable for the real-time control of epidemiological measures due to the time delay from taking the sample until getting a result, which also makes them unsuitable for mass market real-time diagnostics for point-of-care (POC) testing (e.g. medical practices, hospitals, etc.).
Hence Abcalis’ approach for recombinant primary antibodies to be used in antigen based rapid tests. See below how we select and validate our anti-SARS-CoV-2 antibodies:
Regarding antigen based tests, apart from other factors these tests are also partially based on the use of an antibody validated for binding to heat-inactivated virus particles. But the assumption that antibody binding against heat-inactivated virus particles is similar to binding to the native viral protein may underestimate the risk of false positive results.
The solutions from and with Abcalis are therefore qualified to meet regulatory standards and criteria even in the long term, as is the standard with all Abcalis products, since they are all completely sequence defined, implying their unlimited long-term availability and always identical test results. This should allows for a much lower unspecific binding reactivity in many assays compared to animal based products.
Currently, we are offering a variety of different clones with specificities to the S1-, S1+S2-, RBD- as well as N-protein and work with them in different projects for different applications. Simply contact us with your specific needs or request for your setup and we will gladly explore possibilities together!
Plate immobilized recombinant anti-SARS-CoV-2 S1 antibody binding to soluble antigen
Below, four exemplary Abcalis recombinant antibodies against the S1-protein are tested, of which three are specific to the RBD domain and one is specific to the N-terminal domain.
Binding of anti-SARS-CoV-2 N-protein antibody to coated N-protein
Abcalis also features antibodies directed against the N-protein. Below, the binding profile for eight different recombinant antibodies is shown.
Keeping a competitive edge
With Abcalis recombinant antibodies, you are always on the safe side regarding your competition. Below, an exemplary recombinant anti-SARS-CoV-2 antibody of ours was compared to the competition. While both the CR3022 and the ACE2-ECD have been known for binding with high affinity to SARS-CoV-2, our recombinant antibody fits just as well in line with them.
No cross-reactivity to other Coronaviruses
As is crucial in gaining control over the current pandemic and increasing validity of patient test results, Abcalis anti-SARS-CoV-2 antibodies show no unwanted cross-reactivity to other human Coronaviruses, therefore securing the effectiveness of testing and reducing false-positives.
No batch-to-batch variation
With Abcalis antibodies, you can safely ensure product continuity for your portfolio. The data below shows a binding comparison to SARS-CoV-2 S1 or RBD antigens between six different batches of Abcalis antibodies.
Abcalis recombinant anti-SARS-CoV-2 antibodies show supreme shelf-life capabilities
Abcalis antibodies achieve a long shelf life with no impairment to their quality and performance. Below, it is shown that the binding to SARS-CoV-2 S1 antigen is unchanged after storing for the respective conditions as shown below.